← All Innate Pharma SA filings

Innate Pharma SA Schedule 13G passive stakes

Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.

NASDAQ
IPHA
Innate Pharma SA
SCHEDULE: Novo Nordisk Discloses 5.03% Stake in Innate Pharma
Novo Nordisk A/S has reported a beneficial ownership of 5.03% in Innate Pharma SA's ordinary shares as of March 31, 2026.
NASDAQ
IPHA
Innate Pharma SA
SCHEDULE: Novo Nordisk Discloses 7.82% Stake in Innate Pharma
Novo Nordisk A/S has reported a 7.82% beneficial ownership stake in Innate Pharma SA, holding 7,333,778 ordinary shares.
NASDAQ
IPHA
Innate Pharma SA
SCHEDULE: Novo Nordisk Discloses 9.65% Stake in Innate Pharma
Novo Nordisk A/S has disclosed a 9.65% beneficial ownership stake in Innate Pharma SA, as reported in an amended Schedule 13G filing.
NASDAQ
IPHA
Innate Pharma SA
SCHEDULE 13G/A: Sanofi Discloses 9.05% Stake in Innate Pharma SA via Amended SEC Filing
Sanofi has filed an amended Schedule 13G, revealing its beneficial ownership of 9.05% of Innate Pharma SA's ordinary shares as of April 23, 2025.
NASDAQ
IPHA
Innate Pharma SA
SCHEDULE 13G: Sanofi Discloses 9.05% Stake in Innate Pharma SA
Sanofi has filed a Schedule 13G, revealing a beneficial ownership of 9.05% of Innate Pharma SA's ordinary shares.